IL299206A - Methods for treating cancer using heteroaryl-biphenyl amide derivatives - Google Patents
Methods for treating cancer using heteroaryl-biphenyl amide derivativesInfo
- Publication number
- IL299206A IL299206A IL299206A IL29920622A IL299206A IL 299206 A IL299206 A IL 299206A IL 299206 A IL299206 A IL 299206A IL 29920622 A IL29920622 A IL 29920622A IL 299206 A IL299206 A IL 299206A
- Authority
- IL
- Israel
- Prior art keywords
- heteroaryl
- methods
- treating cancer
- amide derivatives
- biphenyl amide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042807P | 2020-06-23 | 2020-06-23 | |
| PCT/US2021/038339 WO2021262627A1 (en) | 2020-06-23 | 2021-06-22 | Methods of treating cancer using heteroaryl-biphenyl amide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299206A true IL299206A (en) | 2023-02-01 |
Family
ID=79022859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299206A IL299206A (en) | 2020-06-23 | 2021-06-22 | Methods for treating cancer using heteroaryl-biphenyl amide derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20210393759A1 (https=) |
| EP (1) | EP4167991A4 (https=) |
| JP (1) | JP7804596B2 (https=) |
| KR (1) | KR20230040993A (https=) |
| CN (1) | CN116472045B (https=) |
| AU (1) | AU2021297216B2 (https=) |
| BR (1) | BR112022026397A2 (https=) |
| CA (1) | CA3187605A1 (https=) |
| CL (1) | CL2022003716A1 (https=) |
| CO (1) | CO2023000703A2 (https=) |
| IL (1) | IL299206A (https=) |
| MX (1) | MX2022016554A (https=) |
| TW (1) | TW202216694A (https=) |
| WO (1) | WO2021262627A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10392405B2 (en) | 2017-08-08 | 2019-08-27 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
| US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
| WO2020232256A1 (en) | 2019-05-15 | 2020-11-19 | Chemocentryx, Inc. | Triaryl compounds for treatment of pd-l1 diseases |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| ES3064674T3 (en) | 2019-10-16 | 2026-04-28 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102448938A (zh) * | 2009-03-27 | 2012-05-09 | 阿迪生物科学公司 | 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺 |
| SG11201402004YA (en) * | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| EP2788000B1 (en) * | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| WO2018119221A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| JP7101678B2 (ja) * | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| CN106674136B (zh) * | 2016-12-23 | 2019-07-02 | 中国医科大学 | 嘧啶类抗肿瘤化合物及其制备方法 |
| US10919852B2 (en) * | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| CA3092362A1 (en) * | 2017-10-19 | 2019-04-25 | Tempest Therapeutics, Inc. | Picolinamide compounds |
| CR20200347A (es) * | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| US10568874B2 (en) * | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
| WO2020232256A1 (en) | 2019-05-15 | 2020-11-19 | Chemocentryx, Inc. | Triaryl compounds for treatment of pd-l1 diseases |
| JP7736678B2 (ja) * | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
-
2021
- 2021-06-22 MX MX2022016554A patent/MX2022016554A/es unknown
- 2021-06-22 CN CN202180059142.3A patent/CN116472045B/zh active Active
- 2021-06-22 JP JP2022579736A patent/JP7804596B2/ja active Active
- 2021-06-22 TW TW110122725A patent/TW202216694A/zh unknown
- 2021-06-22 IL IL299206A patent/IL299206A/en unknown
- 2021-06-22 CA CA3187605A patent/CA3187605A1/en active Pending
- 2021-06-22 KR KR1020237001820A patent/KR20230040993A/ko active Pending
- 2021-06-22 WO PCT/US2021/038339 patent/WO2021262627A1/en not_active Ceased
- 2021-06-22 US US17/354,003 patent/US20210393759A1/en not_active Abandoned
- 2021-06-22 BR BR112022026397A patent/BR112022026397A2/pt unknown
- 2021-06-22 AU AU2021297216A patent/AU2021297216B2/en active Active
- 2021-06-22 EP EP21829047.6A patent/EP4167991A4/en active Pending
-
2022
- 2022-12-22 CL CL2022003716A patent/CL2022003716A1/es unknown
-
2023
- 2023-01-20 CO CONC2023/0000703A patent/CO2023000703A2/es unknown
- 2023-11-15 US US18/509,667 patent/US20240115682A1/en not_active Abandoned
-
2024
- 2024-12-03 US US18/967,429 patent/US20250090646A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202216694A (zh) | 2022-05-01 |
| US20240115682A1 (en) | 2024-04-11 |
| AU2021297216B2 (en) | 2025-10-16 |
| BR112022026397A2 (pt) | 2023-03-14 |
| AU2021297216A1 (en) | 2023-02-02 |
| CO2023000703A2 (es) | 2023-01-26 |
| US20210393759A1 (en) | 2021-12-23 |
| CN116472045A (zh) | 2023-07-21 |
| WO2021262627A1 (en) | 2021-12-30 |
| CN116472045B (zh) | 2025-05-13 |
| CA3187605A1 (en) | 2021-12-30 |
| US20250090646A1 (en) | 2025-03-20 |
| MX2022016554A (es) | 2023-04-10 |
| EP4167991A4 (en) | 2024-07-24 |
| JP7804596B2 (ja) | 2026-01-22 |
| KR20230040993A (ko) | 2023-03-23 |
| CL2022003716A1 (es) | 2023-06-30 |
| EP4167991A1 (en) | 2023-04-26 |
| JP2023531970A (ja) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299206A (en) | Methods for treating cancer using heteroaryl-biphenyl amide derivatives | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| EP4153176A4 (en) | METHODS OF TREATING CANCER | |
| IL300067A (en) | Preparations and methods for the treatment of cancers | |
| EP4111202A4 (en) | CANCER TREATMENT METHODS | |
| IL288665A (en) | Methods for treating cancer using prmt5 inhibitors | |
| IL289811A (en) | A method for treating cancer | |
| IL320217A (en) | Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives | |
| SG11202107017TA (en) | Methods of treating cancer | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| IL305780A (en) | Cancer treatment methods | |
| GB202107994D0 (en) | Treatment of cancer | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| IL312155A (en) | A method for treating cancer | |
| IL272390A (en) | Cancer treatment methods | |
| HK40085038A (en) | Methods of treating cancer using heteroaryl-biphenyl amide derivatives | |
| IL309487A (en) | Methods for determining the effectiveness of cancer treatment | |
| IL312332A (en) | Cancer treatment methods | |
| IL307632A (en) | Cancer treatment methods | |
| IL315569A (en) | Cancer treatment methods | |
| GB202013074D0 (en) | Method of treatment for cancer | |
| GB202118007D0 (en) | Methods of treatment |